OBJECTIVE: To evaluate weight-adjusted strategy for levels of neonatal-17OHP in order to improve newborn screening (NBS) efficiency. SUBJECTS AND METHODS: Blood samples collected between 2-7 days of age from 67,640 newborns were evaluated. When N17OHP levels were ≥ 20 ng/mL, and a second sample was requested. We retrospectively analyzed neonatal-17OHP levels measured by Auto DELFIA- B024-112 assay, grouped according to birth-weight: G1: < 1,500 g, G2: 1,501-2,000 g, G3: 2,000-2,500 g and G4: > 2,500 g. 17OHP cutoff values were determined for each group using the 97.5(th), 99(th), 99.5(th) and 99.8(th) percentiles. RESULTS: 0.5% of newborns presented false-positive results using the cutoff level ≥ 20 ng/mL for all groups. Neonates of low birthweight made up 69% of this group. Seven full-term newborns presented congenital adrenal hyperplasia (CAH) and, except for one of them, 17OHP levels were > 120 ng/mL. Only the 99.8(th) percentile presented higher predictive positive value (2%), and lower rate of false-positives in all groups. CONCLUSIONS: We suggest the use of 99.8(th) percentile obtained by weight-adjusted N17OHP values of healthy newborns to reduce the rate of false-positive results in NBS.
OBJECTIVE: To evaluate weight-adjusted strategy for levels of neonatal-17OHP in order to improve newborn screening (NBS) efficiency. SUBJECTS AND METHODS: Blood samples collected between 2-7 days of age from 67,640 newborns were evaluated. When N17OHP levels were ≥ 20 ng/mL, and a second sample was requested. We retrospectively analyzed neonatal-17OHP levels measured by Auto DELFIA- B024-112 assay, grouped according to birth-weight: G1: < 1,500 g, G2: 1,501-2,000 g, G3: 2,000-2,500 g and G4: > 2,500 g. 17OHP cutoff values were determined for each group using the 97.5(th), 99(th), 99.5(th) and 99.8(th) percentiles. RESULTS: 0.5% of newborns presented false-positive results using the cutoff level ≥ 20 ng/mL for all groups. Neonates of low birthweight made up 69% of this group. Seven full-term newborns presented congenital adrenal hyperplasia (CAH) and, except for one of them, 17OHP levels were > 120 ng/mL. Only the 99.8(th) percentile presented higher predictive positive value (2%), and lower rate of false-positives in all groups. CONCLUSIONS: We suggest the use of 99.8(th) percentile obtained by weight-adjusted N17OHP values of healthy newborns to reduce the rate of false-positive results in NBS.
Authors: John C Achermann; Sorahia Domenice; Tania A S S Bachega; Mirian Y Nishi; Berenice B Mendonca Journal: Nat Rev Endocrinol Date: 2015-05-05 Impact factor: 43.330
Authors: L L Iervolino; B Ferraz-de-Souza; R M Martin; F C Costa; M C Miranda; B B Mendonça; T S Bachega Journal: Osteoporos Int Date: 2020-01-02 Impact factor: 4.507
Authors: Mirela Costa de Miranda; Luciana Bertocco de Paiva Haddad; Evelinda Trindade; Alex Cassenote; Giselle Y Hayashi; Durval Damiani; Fernanda Cavalieri Costa; Guiomar Madureira; Berenice Bilharinho de Mendonca; Tania A S S Bachega Journal: Front Pediatr Date: 2021-05-24 Impact factor: 3.418
Authors: Víctor Clemente Mendoza-Rojas; Luis Alfonso Díaz-Martínez; Gerardo Mantilla-Mora; Gustavo Adolfo Contreras-García; Víctor Manuel Mora-Bautista; Jhon Freddy Martínez-Paredes; Alba Luz Calderón-Rojas; Carlos Augusto Gómez-Tarazona; Katherine Pinzón-Mantilla Journal: Colomb Med (Cali) Date: 2017-12-30